Presentation is loading. Please wait.

Presentation is loading. Please wait.

Human risk assessment perspectives for high risk conditions Jean Lou Dorne Institute of Human Nutrition University of Southampton, UK.

Similar presentations

Presentation on theme: "Human risk assessment perspectives for high risk conditions Jean Lou Dorne Institute of Human Nutrition University of Southampton, UK."— Presentation transcript:


2 Human risk assessment perspectives for high risk conditions Jean Lou Dorne Institute of Human Nutrition University of Southampton, UK

3 Resveratrol Lycopene Allyl sulphides (Allicin…) Isothiocyanates, Sulphorafane Isoflavones Vitamine C, limonene



6 PARACELSUS ( ) All things are toxic and there is nothing without poisonous qualities: it is only the dose which makes something a poison Pharmaco/Toxicokinetics How the chemical is eliminated from the body or activated into a toxic species (ADME) Pharmaco/Toxicodynamics How the chemical exerts its pharmacological effect/ toxicity Target receptor/cell/organ


8 ADI (mg/kg/day) = NOAEL(mg/kg) / 100 Derivation of the Acceptable Daily Intake (ADI)

9 KINETICSDYNAMICSKINETICSDYNAMICS SPECIES DIFFERENCES HUMAN VARIABILITY Extrapolation from group of test animals to average human and from average humans to potentially sensitive sub-populations 10 The use of uncertainty or safety factors (UFs)


11 Towards a more flexible framework Data-derived or Pathway-related Uncertainty factors or general default Data-derived or process related Uncertainty factors or general default Interspecies differences Human variability ToxicokineticsToxicodynamics UFs for main routes of metabolism in test species and humans – intermediate option between default factor and chemical specific adjustment factors Adapted from Dorne and Renwick, 2005 Toxicol Sci 86, 20-26

12 Phase I enzymes Cytochrome P-450, ADH, Esterases % of Pharmaceuticals Metabolized by Individual Cytochrome P450s in man P4502D6 P4501A2 P4502A6 P4503A P4502C9 P4502C19 P4502E1 Phase II enzymes Conjugation reactions Glucuronidation Sulphation N-acetylation (Polymorphic) Amino acid conjugation Renal excretion CYP2C9, CYP2C19, CYP2D6* Polymorphic (Extensive and Poor metabolisers, EMs and PMs) *Caucasian 8% PMs 92% EMs Major Routes of chemical metabolism and excretion

13 Beta Blockers Bufuralol Propafenone Metoprolol propranolol Carvedilol Antiarrhythmics Encainide S-mexiletine Analgesics Dextromethorphan Codeine Tramadol Antidepressants Fluoxetine Paroxetine Amitriptylline Desipramine Imipramine Venlafaxine Pesticides Chlorpyrifos Diazinon Methoxychlor Adapted from Dorne et al., 2002 FCT 41, CYP2D6 Substrates Antipsychotics Risperidone Haloperidol

14 Introducing metabolic and toxicokinetic data into risk assessment

15 Aims Aims Quantify human variability in kinetics for major metabolic routes Markers of chronic exposure (plasma Clearance) Markers of acute exposure (plasma peak concentration Cmax) Prefer the oral route (gut + liver): relevance to environmental contaminants Comparison to the IV route (liver) Identify susceptible subgroups of the population Derive pathway-related uncertainty factors for each subgroup

16 Methods Methods Literature searches Medline, Toxline and EMBASE (1966-current) Compounds metabolised by single route (complete oral absorption, >60% of dose) In vitro metabolism data (cell line, liver microsomes): metabolic route In vivo excretion data: HPLC detects parent compound and metabolites In vivo pharmacokinetic studies for human subgroups

17 Meta-analysis of studies reporting PK parameters for each compound/ parameter/ subgroup of the population: Mean, SD and CV N (normal distribution) transform to geometric mean and GSD, CV LN (lognormal distribution) Derive Coefficient of variation (CV) for each compound/parameter and pool CVs to get overall value for metabolic route (pathway-related variability) Derive Pathway-related uncertainty factors (to cover 95, 97.5 and 99th centiles) using CV and magnitude of difference in internal dose (clearance or Cmax) between healthy adults and subgroups Methods II Methods II

18 Results Results Database for >200 compounds HPLC method for the detection of parent compound and metabolites In vitro metabolism of compound inter-species and human In vivo metabolism data (% excretion for compound and each metabolite HPLC data) Kinetic studies for each compound (> 2500 studies) Subgroups of the human population (healthy adults, genetic polymorphism, interethnic differences, neonates, children and the elderly)

19 Monomorphic pathways Pathway-related UFs below the kinetic default factor (3.2) Low variability in healthy adults (<30%), exception of CYP3A4 : role of gut CYP3A4, P-glycoprotein, polymorphism Pathway n compounds n CVPathway-related UFs (99 th ) CYP1A CYP3A Glucuronidation Renal excretion Healthy adults

20 Pathway n compounds n CVPathway-related UFs (99 th ) CYP2C19 (EM) CYP2C19 (PM) CYP2D6 (EM) CYP2D6 (PM) Polymorphic pathways Variability for polymorphic pathways larger than for monomorphic pathways Large difference in internal dose between EMs and PMs for CYP2D6 (9- fold) and CYP2C19 (12-fold) Pathway-related uncertainty factors above the current kinetic default factor (3.2)

21 Exponential relationships between ratio EM/PM and % CYP2D6 metabolism Ratio EM/PM % CYP2D6 metabolism in EMs PMs covered by pathway-related UFs for substrates with up to 25% (dose) of CYP2D6 metabolism in EMs Quantitative involvement of dose handling on kinetic differences: CYP2D6

22 Quantitative involvement of dose handling on kinetic differences: CYP2C19 PMs covered by UFs for substrates with up to 20-25% (dose) of CYP2C19 metabolism in EMs.

23 Results: Subgroups of the population Interethnic differences Less variability in Asian vs Caucasian for CYP2D6 and CYP2C19 (+ different frequencies of phenotypes) Pathway-related uncertainty factors above kinetic default for CYP2C19 and NAT metabolism Historically smaller database for non-Caucasian subjects: Modern man : mixture of ethnic groups and more so in the future ! Ex relationship for CYP2C19 and ratio EMs/PMs in Asian healthy adults (R 2 =0.87) : Slope 100% metabolism via CYP2C19 gives a ratio of 30 (80 in Caucasian !)

24 Children and neonates Potential susceptible subgroups of the population: -Immaturity of phase I, phase II and renal excretion (particularly for neonates) -Quantify differences in internal dose from in vivo PK database -Provide pathway-related UFs for these subgroups -Identify datagaps

25 Neonates The most susceptible subgroup for all pathways with data: immaturity of phase I, II metabolism and renal excretion. No reliable data available for polymorphic pathways. PathwayNcnCVRatioPathway-related UFs GM95th99th CYP1A CYP3A Glucuronidation Glycine Conjugation Renal excretion All data from the IV route

26 Children Limited data-Susceptible subgroup for both polymorphic CYP2C19 and CYP2D6 PathwayNcnCVRatioPathway-related UFs GM95 th 99th CYP1A2* CYP2C CYP2D CYP3A Glucuronidation Renal Excretion* * IV data (all other data PO route)

27 Polymorphism in metabolism and Children and neonates: Examples Fluoxetine and paroxetine metabolised largely via CYP2D6 and other CYP isoforms (CYP2C9, CYP3A4 and CYP2C19) Large inter-individual differences in kinetics in healthy adults and children: up to fold variation in clearance in healthy adults PMs (including 2 PM children) Holden, C. Prozac Treatment of Newborn Mice Raises Anxiety. Science Oct 29;306(5697):792. Ibuprofen and indomethacin in preterm neonates : up to 10-fold difference decrease in clearance : immature CYP2C9, glucuronidation and renal excretion. Lansoprazole (CYP2C19-CYP3A4): 1 neonate and 1 infant PM (3- and 7-fold decrease in clearance)

28 Predicting human variability in toxicokinetics using Monte Carlo modelling

29 Latin hypercube sampling: variant of Monte Carlo (random), stratified sampling throughout the distribution. Compounds handled by multiple pathways : predict variability and uncertainty factors for healthy adults, children and neonates. Combine distributions describing pathway –related variability and quantitative metabolism data. Compare Simulated data and published kinetic data.

30 Poor metabolisers, neonates and children : -GM ratio of internal dose (mean) compared to healthy adults and pathway-specific variability (GSD) for each pathway. -Neonates and children: ideally use metabolism data but often not available: liver microsome / in vitro and/or healthy adult data -Polymorphic pathways : Combine distribution for EM and PM using frequency of EM and PMs ( for CYP2D6 7.4% PM in Caucasian)

31 Non-phenotyped healthy adults: Uncertainty factors (99 th centile) PublishedSimulated

32 Phenotyped healthy adults: Uncertainty factors (99 th centile) CYP2D6 EMs CYP2D6 PMs Combined EMs and PMs

33 Literature searches for interaction studies between major probe substrates (> 70% of the dose metabolised by each CYP) of CYP2D6 and CYP2C19, inhibitors and inducers of each enzyme. UFs to cover percentiles for subgroup of population Pharmacokinetic interaction between probe substrates of polymorphic CYPs Relevance: a number of pesticides are substrates and inhibit polymorphic CYPs (chlorpyrifos, diazinon).. Extensive metabolisers (EMs) are at risk if the metabolite produced the toxicant. Poor metabolisers (PMs) would be at risk if the parent compound is the toxicant.

34 DRUG A ACTIVE SITE CYP2D6 Cimetidine Cimetidine binds away from active site, changing structure so that Drug A can no longer fits NON-COMPETETIVE CYP2D6 INHIBITION BY CIMETIDINE

35 CYP2D6 DRUG A ACTIVE SITE Paroxetine Paroxetine binds reversibly with drug A to the active site COMPETITIVE INHIBITION OF CYP2D6 BY PAROXETINE

36 CYP Enzyme Induction Hyperforin CYP expression mRNA transcription Pregnane X receptor Retinoid X Receptor Rifampin

37 Polymorphic CYP inhibition CYP2D6 Inhibition will increase internal dose in EMs and UF for toxicokinetic UF (3.16) would not cover this subgroup for binary mixtures. PMs not affected : alternative pathways of metabolism, slow extensive metabolisers (SEMs) are an intermediate

38 INHIBITION/ INDUCTION Inhibition/induction of polymorphic CYP increase/decrease exposure to therapeutic drugs in EMs (and PMs for induction). Current UF for human variability in toxicokinetics (3.16) would not cater for these interactions Results variable ; detailed analysis to classify interaction according to constant of inhibition (Ki) In vivo database on therapeutic doses much higher than pesticide levels but only in vivo data quantifying human variability in toxicokinetic interactions.

39 RELEVANCE TO HUMAN RISK ASSESSMENT Current levels of exposure of organophosphates (< 10 uM) : shown to inhibit imipramine metabolism in human recombinant enzymes and liver microsomes (Di Consiglio et al., 2005). Many pesticides known to either inhibit or induce cytochrome P-450 isoforms in animals and man More work to characterise their potential in vivo effects at the current level of exposure using recombinant technology and toxicokinetic assays (Hodgson and Rose, 2005).

40 CONCLUSIONS CONCLUSIONS Most suceptible subgroups (mixtures) Extensive metabolisers for polymorphic enzymes with inhibitors if metabolite toxic Human data are essential To replace default uncertainty factors with chemical-specific data To identify high risk subgroups regarding susceptibility to chemical toxicity Most susceptible subgroups Poor metabolisers (Healthy adults), neonates, children for polymorphic enzymes but very little data Need for well characterised metabolism before compound on the market Use of in vitro techniques Many pesticides metabolised via polymorphic CYPs

41 Regulatory bodies, Risk managers ? Integrate data (including susceptible subgroups…) in the risk assessment process In vitro, in silico data and OMICS Analysis of toxicodynamics (mechanisms of toxicity) Very little data, use of pharmacodynamic data Advanced statistical techniques Uncertainty analysis, Probabilistic and Bayesian approaches Industry Integrate relevant data (compound specific metabolism PK, PD, TK, TD…) and relevant modelling techniques for risk assessment of compounds before market CONCLUSIONS II CONCLUSIONS II

42 Many thanks to Professor Emeritus Andrew Renwick OBE and -The Department of Health (UK), -Health and Safety Executive (UK), -Food Standard Agency (UK), -European Commission within NO MIRACLE for funding this work


Download ppt "Human risk assessment perspectives for high risk conditions Jean Lou Dorne Institute of Human Nutrition University of Southampton, UK."

Similar presentations

Ads by Google